Publications by authors named "S Protheroe"
Article Synopsis
- IgA vasculitis (IgAV) is a common type of blood vessel disease in kids, and while most get better, some can have long-term kidney problems.
- A group of 28 experts worked for over a year to create guidelines on how to treat IgAV and its complications by reviewing many studies and getting feedback from others.
- The new guidelines have been approved by important health organizations and aim to help doctors provide better care for kids with this condition.
During the COVID-19 pandemic, ibrutinib with or without rituximab was approved in England for initial treatment of mantle cell lymphoma (MCL) instead of immunochemotherapy. Because limited data are available in this setting, we conducted an observational cohort study evaluating safety and efficacy. Adults receiving ibrutinib with or without rituximab for untreated MCL were evaluated for treatment toxicity, response, and survival, including outcomes in high-risk MCL (TP53 mutation/deletion/p53 overexpression, blastoid/pleomorphic, or Ki67 ≥ 30%).
View Article and Find Full Text PDFArticle Synopsis
- Trichohepatoenteric syndrome (THES) is a rare genetic disorder linked to TTC37 or SKIV2L mutations, primarily characterized by congenital diarrhea and multisystem complications.* -
- A study of 13 UK patients diagnosed between 1996 and 2020 showed that while all required parenteral nutrition, some improved over time, with complications including gastrointestinal inflammation and high rates of monogenic inflammatory bowel disease developing by age 11.* -
- Respiratory complications remain a major concern for THES patients, with proper care being essential to reduce associated health risks and improve overall outcomes.*
Objectives: Our objective was to evaluate the short- and long-term safety and efficacy of teduglutide treatment in infants and children with short bowel syndrome with intestinal failure (SBS-IF).
Methods: Two open-label phase 3 studies and 1 extension study investigated the short- and long-term safety and efficacy of teduglutide (0.05 mg/kg/day) in infants and children with SBS-IF: NCT03571516, 24-week study of infants who were randomized to receive teduglutide or standard of care (SoC); NCT02980666, 24-week study of infants and children who all received teduglutide; and NCT03268811, 24-week extension study of patients who completed NCT02980666 (patients could receive up to 48 weeks of total treatment).